Total amount: € 0,00
Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246
Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
Monoclonal antibodies (MAbs) that are reactive with tumor associated antigens have led to many of the recent advances made in tumor immunology. At present, many of these MAbs have already been used in various aspects of patient management and in better understanding the biology of carcinoma cell populations. Because of their diversity, specificity and biological activity, these MAbs are potentially ideal reagents for a variety of applications in malignant disorders such as clinical diagnosis using serum assays, immunocyto pathological analyses of effusions or fine-needle aspiration specimens, biopathological analysis of tumor specimens, immunoscintigraphy and radioimmunoguided surgery.